降血脂 (statin) Primary hypercholesterolaemia, mixed dyslipidaemia (typeIIa and Iib), homozygous familial hypercholesterolaemia and hypertriglyceridemia.

Rosuvastatin is a selective and competitive HMG-CoA reductase inhibitor. It is reportedly less lipophilic than most other statins, being similar in this regard to pravastatin. Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.

The absolute bioavailability of rosuvastatin is about 20%. The volume of distribution is approximately 134 L. 90% is bound to plasma proteins, mainly albumin. Rosuvastatin undergoes minimal hepatic metabolism (about 10%) primarily via CYP450 2C9 and 2C19; there is no metabolism via CYP 3A4, indicating a low propensity for interactions compared to other statins. 90% of the dose is excreted unchanged in the faeces and the remaining excreted in urine. The plasma elimination half-life is about 19 hours.

hypersensitivity to rosuvastatin or to any components of the product; patients with active liver disease or unexplained, persistent elevations of serum transaminases; pregnancy; breast-feeding

X

Do not breastfeed

Common: headache, dizziness, constipation, nausea, abdominal pain, myalgia. Rare: myopathy and rhabdomyolysis.

Initial, 5-10 mg orally once daily; MAX dose 40mg once daily. Dosage adjustment: concomitant cyclosporine: do NOT exceed 5 mg/day; concomitant gemfibrozil: do NOT exceed 10 mg/day; ClCr＜30ml/min non-dialysis: initial 5 mg QD, maintenance not exceed 10 mg /day .

Crestor may be given with or without food at any time of day; if taken with antacids, the antacids should be taken at least 2 hours after Crestor administration.

ClCr＜30ml/min non-dialysis: initial 5 mg QD, maintenance not exceed 10 mg /day